CClinicalTrials.gg
CompletedNCT00155675Updated Jan 12, 2010

Pseudodrynaria Coronana (Wall) Ching

A Phase 1 interventional study of GUSUIBU in Osteoporosis, sponsored by National Taiwan University Hospital. Completed at 1 site in Taiwan. Open to female participants aged 45 Years to 70 Years. Per ClinicalTrials.gov, last updated 2010-01-12.

Sponsored by National Taiwan University Hospital · Phase 1, Interventional, and Treatment

Phase
Phase 1
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
45 Years to 70 Years
Sex
Female
01

Study summary

The Study to evaluate the clinical effect of "Gusuibu" lasts for 3 years. It aims to evaluate its effect on bone density of postmenopausal osteoporosis. Besides, its effects on the liver, kidney and the hematological influence will be evaluated, too.

Read the detailed description

Research of the this traditional chinese medicine clinucal, Gusuibu, curative effect is plan three years time. The entire studyaims to evaluated the effect of the traditional chinese medicine on postmenpausal osteoporosis as well as the possible side effects on the experimental animal and the human body. All subjects were postmenopausal woman with established osteoporosis.

02

Conditions studied

  • Osteoporosis

Browse trials for

03

In context

Osteoporosis

1,640 studies on the registry are indexed under Osteoporosis; 212 are open to participants now.

This study's planned enrollment of 120 is above the median of 95 across 1,133 interventional studies indexed under Osteoporosis.

Browse Osteoporosis studies →

Lead sponsor

National Taiwan University Hospital is the lead sponsor of 2,563 studies on the registry; 569 are open to participants now.

Of its 11 completed or terminated interventional studies of FDA-regulated products, 2 (18%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
45 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • postmenopausal osteoporosis

Exclusion criteria

Exclusion Criteria:

  • Insulin dependent diabetes
05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Double
Enrollment
120 participants (estimated)

Interventions

  • DrugGUSUIBU
06

What researchers measure

Primary outcomes

  1. one year

07

Study locations

1 site
  • National Taiwan University Medical Center
    Taipei, 7, Chung-Shan S. Road 100, Taiwan
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 12, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00155675
Lead sponsor
National Taiwan University Hospital
Collaborators
Sheng Chang Pharmaceutical
First posted
Sep 12, 2005
Start date
Jan 2000
Completion
Jan 2001
Last update
Jan 12, 2010

Study contacts

Liu Hwa-Chang, M.D
study chair · National Taiwan University Medical Center
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion